Abstract
Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC is its intimate association with the gut microbiota, which forms an essential part of the tumour microenvironment. Research over the past decade has established that dysbiosis of gut bacteria, fungi, viruses and Archaea accompanies colorectal tumorigenesis, and these changes might be causative. Data from mechanistic studies demonstrate the ability of the gut microbiota to interact with the colonic epithelia and immune cells of the host via the release of a diverse range of metabolites, proteins and macromolecules that regulate CRC development. Preclinical and some clinical evidence also underscores the role of the gut microbiota in modifying the therapeutic responses of patients with CRC to chemotherapy and immunotherapy. Herein, we summarize our current understanding of the role of gut microbiota in CRC and outline the potential translational and clinical implications for CRC diagnosis, prevention and treatment. Emphasis is placed on how the gut microbiota could now be better harnessed by developing targeted microbial therapeutics as chemopreventive agents against colorectal tumorigenesis, as adjuvants for chemotherapy and immunotherapy to boost drug efficacy and safety, and as non-invasive biomarkers for CRC screening and patient stratification. Finally, we highlight the hurdles and potential solutions to translating our knowledge of the gut microbiota into clinical practice.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sender, R., Fuchs, S. & Milo, R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164, 337–340 (2016).
Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804–810 (2007).
Wu, H. J. & Wu, E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3, 4–14 (2012).
Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M. & Owen, L. J. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 26, 26191 (2015).
Scott, A. J. et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut 68, 1624–1632 (2019).
Dai, Z. et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 6, 70 (2018).
Feng, Q. et al. Gut microbiome development along the colorectal adenoma–carcinoma sequence. Nat. Commun. 6, 6528 (2015).
Yu, J. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 66, 70–78 (2017).
Sobhani, I. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE 6, e16393 (2011).
Wang, T. et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6, 320–329 (2012).
Ahn, J. et al. Human gut microbiome and risk for colorectal cancer. J. Natl Cancer Inst. 105, 1907–1911 (2013).
Zeller, G. et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol. Syst. Biol. 10, 766 (2014).
Zackular, J. P., Rogers, M. A. M., Ruffin, M. T. & Schloss, P. D. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev. Res. 7, 1112–1121 (2014).
Baxter, N. T., Ruffin, M. T., Rogers, M. A. M. & Schloss, P. D. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med. https://doi.org/10.1186/s13073-016-0290-3 (2016).
Yazici, C. et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut 66, 1983–1994 (2017).
Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019).
Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679 (2019).
Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968 (2019).
Chen, W., Liu, F., Ling, Z., Tong, X. & Xiang, C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE 7, e39743 (2012).
Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).
Warren, R. L. et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 1, 16 (2013).
Zhang, Z. et al. Spatial heterogeneity and co-occurrence patterns of human mucosal-associated intestinal microbiota. ISME J. 8, 881–893 (2014).
Nakatsu, G. et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun. 6, 8727 (2015).
Flemer, B. et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66, 633–643 (2017).
Drewes, J. L. et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microbiomes https://doi.org/10.1038/s41522-017-0040-3 (2017).
McCoy, A. N. et al. Fusobacterium is associated with colorectal adenomas. PLoS ONE https://doi.org/10.1371/journal.pone.0053653 (2013).
Liang, J. Q. et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut 69, 1248–1257 (2020).
Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15, 1016–1022 (2009).
Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012).
Boleij, A. & Tjalsma, H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect. Dis. 13, 719–724 (2013).
Cao, Y. et al. Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites. Science 378, eabm3233 (2022).
Correa, N. B., Peret Filho, L. A., Penna, F. J., Lima, F. M. & Nicoli, J. R. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J. Clin. Gastroenterol. 39, 385–389 (2005).
Horz, H. P., Meinelt, A., Houben, B. & Conrads, G. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral. Microbiol. Immunol. 22, 126–130 (2007).
Roy, D., Ward, P., Vincent, D. & Mondou, F. Molecular identification of potentially probiotic lactobacilli. Curr. Microbiol. 40, 40–46 (2000).
Szajewska, H., Ruszczynski, M. & Radzikowski, A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J. Pediatr. 149, 367–372 (2006).
Pilchova, T., Pilet, M.-F., Cappelier, J.-M., Pazlarová, J. & Tresse, O. Protective effect of Carnobacterium spp. against Listeria monocytogenes during host cell invasion using in vitro HT29 model. Front. Cell. Infect. Microbiol. 6, 88 (2016).
Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).
Liu, W. et al. Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis. Gastroenterology 160, 2395–2408 (2021).
Okuda, S. et al. Profiling of host genetic alterations and intra-tumor microbiomes in colorectal cancer. Comput. Struct. Biotechnol. J. 19, 3330–3338 (2021).
Burns, M. B., Lynch, J., Starr, T. K., Knights, D. & Blekhman, R. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome Med. 7, 55 (2015).
Kosumi, K. et al. The amount of Bifidobacterium genus in colorectal carcinoma tissue in relation to tumor characteristics and clinical outcome. Am. J. Pathol. 188, 2839–2852 (2018).
Yamamoto, S. et al. Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer. J. Gastroenterol. Hepatol. 36, 1869–1876 (2021).
Galeano Nino, J. L. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611, 810–817 (2022).
Shkoporov, A. N. & Hill, C. Bacteriophages of the human gut: the “known unknown” of the microbiome. Cell Host Microbe 25, 195–209 (2019).
Salyakina, D. & Tsinoremas, N. F. Viral expression associated with gastrointestinal adenocarcinomas in TCGA high-throughput sequencing data. Hum. Genomics 7, 23 (2013).
Bodaghi, S. et al. Colorectal papillomavirus infection in patients with colorectal cancer. Clin. Cancer Res. 11, 2862–2867 (2005).
Goel, A. et al. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology 130, 1950–1961 (2006).
Shkoporov, A. N., Turkington, C. J. & Hill, C. Mutualistic interplay between bacteriophages and bacteria in the human gut. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-022-00755-4 (2022).
Nakatsu, G. et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology 155, 529–541.e5 (2018).
Niu, Y. D., McAllister, T. A., Nash, J. H., Kropinski, A. M. & Stanford, K. Four Escherichia coli O157:H7 phages: a new bacteriophage genus and taxonomic classification of T1-like phages. PLoS ONE 9, e100426 (2014).
Hannigan, G. D., Duhaime, M. B., Ruffin, M. T. T., Koumpouras, C. C. & Schloss, P. D. Diagnostic potential and interactive dynamics of the colorectal cancer virome. mBio https://doi.org/10.1128/mBio.02248-18 (2018).
Chen, F. et al. Meta-analysis of fecal viromes demonstrates high diagnostic potential of the gut viral signatures for colorectal cancer and adenoma risk assessment. J. Adv. Res. https://doi.org/10.1016/j.jare.2022.09.012 (2022).
Lin, Y. et al. Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology 163, 908–921 (2022).
Anandakumar, A., Pellino, G., Tekkis, P. & Kontovounisios, C. Fungal microbiome in colorectal cancer: a systematic review. Updates Surg. 71, 625–630 (2019).
Coker, O. O. et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut 68, 654–662 (2019).
Gao, R. et al. Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis. 36, 2457–2468 (2017).
Luan, C. et al. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. Sci. Rep. 5, 7980 (2015).
Liu, N. N. et al. Multi-kingdom microbiota analyses identify bacterial–fungal interactions and biomarkers of colorectal cancer across cohorts. Nat. Microbiol. 7, 238–250 (2022).
Deveau, A. et al. Bacterial–fungal interactions: ecology, mechanisms and challenges. FEMS Microbiol. Rev. 42, 335–352 (2018).
Eme, L., Spang, A., Lombard, J., Stairs, C. W. & Ettema, T. J. G. Archaea and the origin of eukaryotes. Nat. Rev. Microbiol. 15, 711–723 (2017).
Evans, P. N. et al. An evolving view of methane metabolism in the Archaea. Nat. Rev. Microbiol. 17, 219–232 (2019).
Hoegenauer, C., Hammer, H. F., Mahnert, A. & Moissl-Eichinger, C. Methanogenic Archaea in the human gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-022-00673-z (2022).
Nakamura, N., Lin, H. C., McSweeney, C. S., Mackie, R. I. & Gaskins, H. R. Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease. Annu. Rev. Food Sci. Technol. 1, 363–395 (2010).
Coker, O. O., Wu, W. K. K., Wong, S. H., Sung, J. J. Y. & Yu, J. Altered gut Archaea composition and interaction with bacteria are associated with colorectal cancer. Gastroenterology 159, 1459–1470.e5 (2020).
Llorens-Rico, V., Simcock, J. A., Huys, G. R. B. & Raes, J. Single-cell approaches in human microbiome research. Cell 185, 2725–2738 (2022).
Epstein, S. S. The phenomenon of microbial uncultivability. Curr. Opin. Microbiol. 16, 636–642 (2013).
Parks, D. H. et al. Recovery of nearly 8,000 metagenome-assembled genomes substantially expands the tree of life. Nat. Microbiol. 2, 1533–1542 (2017).
Almeida, A. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat. Biotechnol. 39, 105–114 (2021).
Saheb Kashaf, S. et al. Integrating cultivation and metagenomics for a multi-kingdom view of skin microbiome diversity and functions. Nat. Microbiol. 7, 169–179 (2022).
Zhu, J. et al. Over 50,000 metagenomically assembled draft genomes for the human oral microbiome reveal new taxa. Genomics Proteom. Bioinforma. https://doi.org/10.1016/j.gpb.2021.05.001 (2021).
Villa, M. M. et al. Interindividual variation in dietary carbohydrate metabolism by gut bacteria revealed with droplet microfluidic culture. mSystems https://doi.org/10.1128/mSystems.00864-19 (2020).
Watterson, W. J. et al. Droplet-based high-throughput cultivation for accurate screening of antibiotic resistant gut microbes. Elife https://doi.org/10.7554/eLife.56998 (2020).
Lan, F., Demaree, B., Ahmed, N. & Abate, A. R. Single-cell genome sequencing at ultra-high-throughput with microfluidic droplet barcoding. Nat. Biotechnol. 35, 640–646 (2017).
Ma, L. et al. Gene-targeted microfluidic cultivation validated by isolation of a gut bacterium listed in Human Microbiome Project’s Most Wanted taxa. Proc. Natl Acad. Sci. USA 111, 9768–9773 (2014).
Zheng, W. et al. High-throughput, single-microbe genomics with strain resolution, applied to a human gut microbiome. Science 376, eabm1483 (2022).
Chijiiwa, R. et al. Single-cell genomics of uncultured bacteria reveals dietary fiber responders in the mouse gut microbiota. Microbiome 8, 5 (2020).
Wong, S. H. et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153, 1621–1633.e6 (2017).
Li, L. et al. Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apcmin/+ mice. EBioMedicine 48, 301–315 (2019).
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. https://doi.org/10.15252/embr.201847638 (2019).
Guo, P. et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J. Exp. Clin. Cancer Res. 39, 202 (2020).
Abed, J. et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 20, 215–225 (2016).
Casasanta, M. A. et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci. Signal https://doi.org/10.1126/scisignal.aba9157 (2020).
Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355 (2015).
Nougayrede, J. P. et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313, 848–851 (2006).
Cuevas-Ramos, G. et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl Acad. Sci. USA 107, 11537–11542 (2010).
Iftekhar, A. et al. Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells. Nat. Commun. 12, 1003 (2021).
Cougnoux, A. et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 63, 1932–1942 (2014).
Lucas, C. et al. Autophagy of intestinal epithelial cells inhibits colorectal carcinogenesis induced by colibactin-producing Escherichia coli in ApcMin/+ mice. Gastroenterology 158, 1373–1388 (2020).
Lopes, A. et al. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. Int. J. Cancer 146, 3147–3159 (2020).
Tsoi, H. et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 152, 1419–1433.e5 (2017).
Long, X. et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat. Microbiol. 4, 2319–2330 (2019).
Chung, L. et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23, 203–214.e5 (2018).
Geis, A. L. et al. Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov. 5, 1098–1109 (2015).
Cao, Y. et al. Enterotoxigenic Bacteroides fragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p. Gastroenterology https://doi.org/10.1053/j.gastro.2021.08.003 (2021).
Hwang, S. et al. Enterotoxigenic Bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model. Int. J. Med. Sci. 17, 145–152 (2020).
Thiele Orberg, E. et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 10, 421–433 (2017).
Yang, J. et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology 162, 135 (2022).
Bai, X. W. et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites. Gut https://doi.org/10.1136/gutjnl-2021-325021 (2022).
Akyol, A. et al. Generating somatic mosaicism with a Cre recombinase-microsatellite sequence transgene. Nat. Methods 5, 231–233 (2008).
Xue, Y., Johnson, R., Desmet, M., Snyder, P. W. & Fleet, J. C. Generation of a transgenic mouse for colorectal cancer research with intestinal Cre expression limited to the large intestine. Mol. Cancer Res. 8, 1095–1104 (2010).
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Nesic, D., Hsu, Y. & Stebbins, C. E. Assembly and function of a bacterial genotoxin. Nature 429, 429–433 (2004).
Johnson, W. M. & Lior, H. A new heat-labile cytolethal distending toxin (CLDT) produced by Escherichia coli isolates from clinical material. Microb. Pathog. 4, 103–113 (1988).
He, Z. et al. Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut 68, 289–300 (2019).
Wilson, M. R. et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science https://doi.org/10.1126/science.aar7785 (2019).
Xue, M. et al. Structure elucidation of colibactin and its DNA cross-links. Science https://doi.org/10.1126/science.aax2685 (2019).
Dziubanska-Kusibab, P. J. et al. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer. Nat. Med. 26, 1063–1069 (2020).
Pleguezuelos-Manzano, C. et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature 580, 269–273 (2020).
Dejea, C. M. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359, 592–597 (2018).
Cougnoux, A. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut 65, 278–285 (2016).
Volpe, M. R. et al. A small molecule inhibitor prevents gut bacterial genotoxin production. Nat. Chem. Biol. https://doi.org/10.1038/s41589-022-01147-8 (2022).
Goodwin, A. C. et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl Acad. Sci. USA 108, 15354–15359 (2011).
Wang, X. & Huycke, M. M. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132, 551–561 (2007).
Maddocks, O. D., Scanlon, K. M. & Donnenberg, M. S. An Escherichia coli effector protein promotes host mutation via depletion of DNA mismatch repair proteins. mBio 4, e00152-13 (2013).
Ikegami, A., Chung, P. & Han, Y. P. W. Complementation of the fadA mutation in Fusobacterium nucleatum demonstrates that the surface-exposed adhesin promotes cellular invasion and placental colonization. Infect. Immun. 77, 3075–3079 (2009).
Xu, M. H. et al. FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells. J. Biol. Chem. 282, 25000–25009 (2007).
Mu, W. et al. Intracellular Porphyromonas gingivalis promotes the proliferation of colorectal cancer cells via the MAPK/ERK signaling pathway. Front. Cell Infect. Microbiol. 10, 584798 (2020).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Lasry, A., Zinger, A. & Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 17, 230–240 (2016).
Ruiz, P. A., Anna, S., Kim, S. C., Sartor, R. B. & Haller, D. IL-10 gene-deficient mice lack TGF-β/Smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic Enterococcus faecalis. J. Immunol. 174, 2990–2999 (2005).
Zhao, L. et al. Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients. Oncogene 41, 4200–4210 (2022).
DeStefano Shields, C. E. et al. Bacterial-driven inflammation and mutant BRAF expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy. Cancer Discov. 11, 1792–1807 (2021).
Arthur, J. C. et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5, 4724 (2014).
Zou, J. & Shankar, N. Roles of TLR/MyD88/MAPK/NF-κB signaling pathways in the regulation of phagocytosis and proinflammatory cytokine expression in response to E. faecalis infection. PLoS ONE 10, e0136947 (2015).
Xia, Y. F., Shen, S. & Verma, I. M. NF-κB, an active player in human cancers. Cancer Immunol. Res. 2, 823–830 (2014).
Couturier-Maillard, A. et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 123, 700–711 (2013).
Udden, S. M. N. et al. NOD2 suppresses colorectal tumorigenesis via downregulation of the TLR pathways. Cell Rep. 19, 2756–2770 (2017).
Chen, G. Y., Shaw, M. H., Redondo, G. & Nunez, G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 68, 10060–10067 (2008).
Martin, T. D. et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science 373, 1327 (2021).
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).
Zhang, Q. et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov. 11, 1248–1267 (2021).
Schneider, K. M. et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat. Commun. 13, 3964 (2022).
Peuker, K. et al. Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity 55, 701–717.e7 (2022).
Wang, T. T. et al. The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity 49, 504–514.e4 (2018).
Xu, C. C. et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes https://doi.org/10.1080/19490976.2021.1980347 (2021).
Chiang, M. K. et al. Two ST11 Klebsiella pneumoniae strains exacerbate colorectal tumorigenesis in a colitis-associated mouse model. Gut Microbes 13, 1980348 (2021).
Jones, B. V., Begley, M., Hill, C., Gahan, C. G. & Marchesi, J. R. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc. Natl Acad. Sci. USA 105, 13580–13585 (2008).
Ridlon, J. M. & Hylemon, P. B. Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium. J. Lipid Res. 53, 66–76 (2012).
Ou, J. H. et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am. J. Clin. Nutr. 98, 111–120 (2013).
Payne, C. M., Bernstein, C., Dvorak, K. & Bernstein, H. Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis. Clin. Exp. Gastroenterol. 1, 19–47 (2008).
Booth, L. A., Gilmore, I. T. & Bilton, R. F. Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved? Free Radic. Res. 26, 135–144 (1997).
Turner, D. J. et al. Bile salts induce resistance to apoptosis through NF-κB-mediated XIAP expression. Ann. Surg. 245, 415–425 (2007).
Bernstein, C. et al. Carcinogenicity of deoxycholate, a secondary bile acid. Arch. Toxicol. 85, 863–871 (2011).
Cao, H. et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int. J. Cancer 140, 2545–2556 (2017).
Islam, K. B. M. S. et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141, 1773–1781 (2011).
Lee, J. Y. et al. Contribution of the 7β-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon. J. Lipid Res. 54, 3062–3069 (2013).
Wali, R. K. et al. Ursodeoxycholic acid and F6-D3 inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol. Biomark. Prev. 11, 1653–1662 (2002).
Peiro-Jordan, R. et al. The chemopreventive agent ursodeoxycholic acid inhibits proliferation of colon carcinoma cells by suppressing c-Myc expression. Eur. J. Cancer Prev. 21, 413–422 (2012).
Kim, E. K., Cho, J. H., Kim, E. & Kim, Y. J. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS ONE https://doi.org/10.1371/journal.pone.0181183 (2017).
Marquet, P., Duncan, S. H., Chassard, C., Bernalier-Donadille, A. & Flint, H. J. Lactate has the potential to promote hydrogen sulphide formation in the human colon. FEMS Microbiol. Lett. 299, 128–134 (2009).
Braccia, D. J., Jiang, X. F., Pop, M. & Hall, A. B. The capacity to produce hydrogen sulfide (H2S) via cysteine degradation is ubiquitous in the human gut microbiome. Front. Microbiol. https://doi.org/10.3389/fmicb.2021.705583 (2021).
Laue, H., Denger, K. & Cook, A. M. Taurine reduction in anaerobic respiration of Bilophila wadsworthia RZATAU. Appl. Environ. Microbiol. 63, 2016–2021 (1997).
David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
Nguyen, L. H. et al. Association between sulfur-metabolizing bacterial communities in stool and risk of distal colorectal cancer in men. Gastroenterology 158, 1313–1325 (2020).
Nguyen, L. H. et al. The sulfur microbial diet is associated with increased risk of early-onset colorectal cancer precursors. Gastroenterology 161, 1423–1432.e4 (2021).
Attene-Ramos, M. S. et al. DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. Environ. Mol. Mutagen. 51, 304–314 (2010).
Attene-Ramos, M. S., Wagner, E. D., Gaskins, H. R. & Plewa, M. J. Hydrogen sulfide induces direct radical-associated DNA damage. Mol. Cancer Res. 5, 455–459 (2007).
Cai, W. J., Wang, M. J., Ju, L. H., Wang, C. & Zhu, Y. C. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol. Int. 34, 565–572 (2010).
Chen, F. et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut 71, 1315–1325 (2022).
Kong, C. et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut https://doi.org/10.1136/gutjnl-2022-327156 (2022).
Gao, R. et al. Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites. Gastroenterology 163, 1024–1037.e9 (2022).
Coker, O. O. et al. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome https://doi.org/10.1186/s40168-021-01208-5 (2022).
Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215 (2018).
Purcell, R. V., Visnovska, M., Biggs, P. J., Schmeier, S. & Frizelle, F. A. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci. Rep. 7, 11590 (2017).
Gao, R. et al. Mucosa-associated microbiota signature in colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis. 36, 2073–2083 (2017).
Yuan, D. et al. A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer. Invest. N. Drugs 40, 884–894 (2022).
Kadosh, E. et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature 586, 133–138 (2020).
Li, C. et al. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut 71, 2253–2265 (2022).
Sobhani, I. et al. Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures. Proc. Natl Acad. Sci. USA 116, 24285–24295 (2019).
Maiuri, A. R. et al. Mismatch repair proteins initiate epigenetic alterations during inflammation-driven tumorigenesis. Cancer Res. 77, 3467–3478 (2017).
Park, H. E., Kim, J. H., Cho, N. Y., Lee, H. S. & Kang, G. H. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 471, 329–336 (2017).
Xia, X. X. et al. Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer. Microbiome https://doi.org/10.1186/s40168-020-00847-4 (2020).
Yuan, C., Burns, M. B., Subramanian, S. & Blekhman, R. Interaction between host microRNAs and the gut microbiota in colorectal cancer. Msystems 3, e00205-17 (2018).
Yang, Y. Z. et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology 152, 851–866.e24 (2017).
Hong, J. et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut 70, 2123–2137 (2021).
Liu, S. et al. The host shapes the gut microbiota via fecal microRNA. Cell Host Microbe 19, 32–43 (2016).
Tomkovich, S. et al. Human colon mucosal biofilms and murine host communicate via altered mRNA and microRNA expression during cancer. Msystems https://doi.org/10.1128/mSystems.00451-19 (2020).
Chen, S. et al. Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis. Nat. Commun. 13, 1248 (2022).
Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514 (2014).
Goldin, B. R. & Gorbach, S. L. Effect of Lactobacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochloride-induced intestinal cancer in rats. J. Natl Cancer Inst. 64, 263–265 (1980).
Rao, C. V., Sanders, M. E., Indranie, C., Simi, B. & Reddy, B. S. Prevention of colonic preneoplastic lesions by the probiotic Lactobacillus acidophilus NCFMTM in F344 rats. Int. J. Oncol. 14, 939–944 (1999).
Goldin, B. R., Gualtieri, L. J. & Moore, R. P. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr. Cancer 25, 197–204 (1996).
Koo, M. & Rao, A. V. Long-term effect of Bifidobacteria and Neosugar on precursor lesions of colonic cancer in CF1 mice. Nutr. Cancer 16, 249–257 (1991).
Singh, J. et al. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 18, 833–841 (1997).
Rowland, I. R., Rumney, C. J., Coutts, J. T. & Lievense, L. C. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 19, 281–285 (1998).
Ishikawa, H. et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int. J. Cancer 116, 762–767 (2005).
Rafter, J. et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am. J. Clin. Nutr. 85, 488–496 (2007).
O’Toole, P. W., Marchesi, J. R. & Hill, C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat. Microbiol. 2, 17057 (2017).
Wan, Y. et al. Fermentation supernatants of Lactobacillus delbrueckii inhibit growth of human colon cancer cells and induce apoptosis through a caspase 3-dependent pathway. Oncol. Lett. 7, 1738–1742 (2014).
Wang, S. M. et al. Induction of HT-29 cells apoptosis by lactobacilli isolated from fermented products. Res. Microbiol. 165, 202–214 (2014).
Nami, Y. et al. Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium Lactobacillus plantarum 5BL. Microbiol. Immunol. 58, 492–502 (2014).
Tiptiri-Kourpeti, A. et al. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PLoS ONE 11, e0147960 (2016).
Orlando, A. et al. Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2.1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines. Nutr. Cancer 64, 1103–1111 (2012).
Karimi Ardestani, S., Tafvizi, F. & Tajabadi Ebrahimi, M. Heat-killed probiotic bacteria induce apoptosis of HT-29 human colon adenocarcinoma cell line via the regulation of Bax/Bcl2 and caspases pathway. Hum. Exp. Toxicol. 38, 1069–1081 (2019).
Chung, I. C. et al. Pretreatment with a heat-killed probiotic modulates the NLRP3 inflammasome and attenuates colitis-associated colorectal cancer in mice. Nutrients https://doi.org/10.3390/nu11030516 (2019).
Vital, M., Karch, A. & Pieper, D. H. Colonic butyrate-producing communities in humans: an overview using omics data. mSystems https://doi.org/10.1128/mSystems.00130-17 (2017).
Donohoe, D. R. et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 4, 1387–1397 (2014).
Archer, S. Y., Meng, S., Shei, A. & Hodin, R. A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl Acad. Sci. USA 95, 6791–6796 (1998).
Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M. & Kim, C. H. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145, 396–406.e10 (2013).
Zhao, Y. et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 11, 752–762 (2018).
Singh, N. et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128–139 (2014).
Tang, Y., Chen, Y., Jiang, H., Robbins, G. T. & Nie, D. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int. J. Cancer 128, 847–856 (2011).
Chen, D. et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. Cancer Lett. 469, 456–467 (2020).
Sivaprakasam, S. et al. An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis. Oncogenesis 5, e238 (2016).
Konishi, H. et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat. Commun. 7, 12365 (2016).
Sugimura, N. et al. Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut https://doi.org/10.1136/gutjnl-2020-323951 (2021).
Bell, H. N. et al. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell 40, 185–200.e6 (2022).
Sakatani, A. et al. Polyphosphate derived from Lactobacillus brevis inhibits colon cancer progression through induction of cell apoptosis. Anticancer. Res. 36, 591–598 (2016).
Kashima, S. et al. Polyphosphate, an active molecule derived from probiotic Lactobacillus brevis, improves the fibrosis in murine colitis. Transl. Res. 166, 163–175 (2015).
Ahmadi, S., Ghollasi, M. & Hosseini, H. M. The apoptotic impact of nisin as a potent bacteriocin on the colon cancer cells. Microb. Pathog. 111, 193–197 (2017).
Cao, K. Y. et al. Antitumor activities of tRNA-derived fragments and tRNA halves from non-pathogenic Escherichia coli strains on colorectal cancer and their structure–activity relationship. mSystems 7, e0016422 (2022).
Li, Q. et al. Streptococcus thermophilus inhibits colorectal tumorigenesis through secreting β-galactosidase. Gastroenterology 160, 1179–1193.e14 (2021).
Di, W. et al. Exopolysaccharides produced by Lactobacillus strains suppress HT-29 cell growth via induction of G0/G1 cell cycle arrest and apoptosis. Oncol. Lett. 16, 3577–3586 (2018).
Kim, Y., Oh, S., Yun, H. S., Oh, S. & Kim, S. H. Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett. Appl. Microbiol. 51, 123–130 (2010).
El-Deeb, N. M., Yassin, A. M., Al-Madboly, L. A. & El-Hawiet, A. A novel purified Lactobacillus acidophilus 20079 exopolysaccharide, LA-EPS-20079, molecularly regulates both apoptotic and NF-κB inflammatory pathways in human colon cancer. Microb. Cell Fact. 17, 29 (2018).
Di, W. et al. Physicochemical characterization and antitumour activity of exopolysaccharides produced by Lactobacillus casei SB27 from yak milk. Carbohydr. Polym. 171, 307–315 (2017).
Li, F. et al. Antitumor mechanisms of an exopolysaccharide from Lactobacillus fermentum on HT-29 cells and HT-29 tumor-bearing mice. Int. J. Biol. Macromol. 209, 552–562 (2022).
Li, W. et al. Characterization of a novel polysaccharide with anti-colon cancer activity from Lactobacillus helveticus MB2-1. Carbohydr. Res. 411, 6–14 (2015).
Xiao, L. et al. Anticancer potential of an exopolysaccharide from Lactobacillus helveticus MB2-1 on human colon cancer HT-29 cells via apoptosis induction. Food Funct. 11, 10170–10181 (2020).
Song, W. et al. Oxidative stress and endoplasmic reticulum stress contribute to L. paracasei subsp. paracasei M5L exopolysaccharide-induced apoptosis in HT-29 cells. Food Sci. Nutr. 9, 1676–1687 (2021).
Sun, M. et al. The effects of Lactobacillus plantarum-12 crude exopolysaccharides on the cell proliferation and apoptosis of human colon cancer (HT-29) cells. Probiotics Antimicrob. Proteins 13, 413–421 (2021).
Tukenmez, U., Aktas, B., Aslim, B. & Yavuz, S. The relationship between the structural characteristics of lactobacilli-EPS and its ability to induce apoptosis in colon cancer cells in vitro. Sci. Rep. 9, 8268 (2019).
Deepak, V. et al. Exopolysaccharides from Lactobacillus acidophilus modulates the antioxidant status of 1,2-dimethyl hydrazine-induced colon cancer rat model. 3 Biotech 11, 225 (2021).
Tian, P. J. et al. Extraction of peptidoglycan from L. paracasei subp. paracasei X12 and its preliminary mechanisms of inducing immunogenic cell death in HT-29 cells. Int. J. Mol. Sci. 16, 20033–20049 (2015).
Schmitt, M. & Greten, F. R. The inflammatory pathogenesis of colorectal cancer. Nat. Rev. Immunol. 21, 653–667 (2021).
Gamallat, Y. et al. Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed. Pharmacother. 83, 536–541 (2016).
Kuugbee, E. D. et al. Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer. Dig. Dis. Sci. 61, 2908–2920 (2016).
Do, E. J. et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J. Gastroenterol. Hepatol. 31, 1453–1461 (2016).
Chung, E. J. et al. Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice. Eur. J. Pharmacol. 794, 1–7 (2017).
Del Carmen, S., de Moreno de LeBlanc, A. & LeBlanc, J. G. Development of a potential probiotic yoghurt using selected anti-inflammatory lactic acid bacteria for prevention of colitis and carcinogenesis in mice. J. Appl. Microbiol. 121, 821–830 (2016).
Jacouton, E., Chain, F., Sokol, H., Langella, P. & Bermudez-Humaran, L. G. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front. Immunol. 8, 1553 (2017).
Del Carmen, S. et al. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. Int. Immunopharmacol. 42, 122–129 (2017).
Mohamadzadeh, M. et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl Acad. Sci. USA 108, 4623–4630 (2011).
Khazaie, K. et al. Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl Acad. Sci. USA 109, 10462–10467 (2012).
Ni, Y. et al. A metagenomic study of the preventive effect of Lactobacillus rhamnosus GG on intestinal polyp formation in ApcMin/+ mice. J. Appl. Microbiol. 122, 770–784 (2017).
Wang, T. et al. Lacticaseibacillus rhamnosus LS8 ameliorates azoxymethane/dextran sulfate sodium-induced colitis-associated tumorigenesis in mice via regulating gut microbiota and inhibiting inflammation. Probiotics Antimicrob. Proteins 14, 947–959 (2022).
Liu, X. et al. Early life Lactobacillus rhamnosus GG colonisation inhibits intestinal tumour formation. Br. J. Cancer 126, 1421–1431 (2022).
Hibberd, A. A. et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open. Gastroenterol. 4, e000145 (2017).
Sorbara, M. T. & Pamer, E. G. Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. Mucosal Immunol. 12, 1–9 (2019).
Byndloss, M. X. et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357, 570–575 (2017).
Lawrence, G. W. et al. Effect of a bacteriocin-producing Streptococcus salivarius on the pathogen Fusobacterium nucleatum in a model of the human distal colon. Gut Microbes 14, 2100203 (2022).
Lee, J. W. et al. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. J. Vet. Sci. 5, 41–48 (2004).
Owens, J. A. et al. Lactobacillus rhamnosus GG orchestrates an antitumor immune response. Cell Mol. Gastroenterol. Hepatol. 12, 1311–1327 (2021).
Montalban-Arques, A. et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 29, 1573–1588.e7 (2021).
Wang, L. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice. Gut 69, 1988–1997 (2020).
Fan, L. et al. A. muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs. Cancer Immunol. Res. 9, 1111–1124 (2021).
Katona, B. W. & Weiss, J. M. Chemoprevention of colorectal cancer. Gastroenterology 158, 368–388 (2020).
Prizment, A. E. et al. Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. Aliment. Pharmacol. Ther. 52, 976–987 (2020).
Brennan, C. A. et al. Aspirin modulation of the colorectal cancer-associated microbe Fusobacterium nucleatum. mBio https://doi.org/10.1128/mBio.00547-21 (2021).
Zhao, R. et al. Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects. Gastroenterology 159, 969–983.e4 (2020).
Garcia-Gonzalez, A. P. et al. Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell 169, 431–441.e8 (2017).
Hou, X. Y. et al. Prevotella contributes to individual response of FOLFOX in colon cancer. Clin. Transl. Med. 11, e512 (2021).
Zhang, S. et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J. Exp. Clin. Cancer Res. 38, 14 (2019).
Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563.e16 (2017).
Scott, T. A. et al. Host–microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell 169, 442–456.e18 (2017).
Zheng, D. W. et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 3, 717–728 (2019).
He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab. 33, 988–1000.e7 (2021).
Yoon, Y., Kim, G., Jeon, B. N., Fang, S. & Park, H. Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice. Cancers https://doi.org/10.3390/cancers13050957 (2021).
Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020).
Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).
Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).
Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).
Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
LaCourse, K. D. et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 41, 111625 (2022).
Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299–306 (2012).
Ramos, A. & Hemann, M. T. Drugs, bugs, and cancer: Fusobacterium nucleatum promotes chemoresistance in colorectal cancer. Cell 170, 411–413 (2017).
Chu, Z. L. et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl Acad. Sci. USA 94, 10057–10062 (1997).
Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. Jr NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680–1683 (1998).
Pang, R. et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6, 603–615 (2010).
Liu, H. et al. Fusobacterium nucleatum promotes colorectal cancer cell to acquire stem cell-like features by manipulating lipid droplet-mediated numb degradation. Adv. Sci. 9, e2105222 (2022).
Ternes, D. et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat. Metab. 4, 458–475 (2022).
Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15–25 (2014).
Nagata, S. & Tanaka, M. Programmed cell death and the immune system. Nat. Rev. Immunol. 17, 333–340 (2017).
Wang, Y. J., Fletcher, R., Yu, J. & Zhang, L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes. Dis. 5, 194–203 (2018).
Wang, Z., Till, B. & Gao, Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology 6, e1331807 (2017).
Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
Barbet, G. et al. Sensing microbial viability through bacterial RNA augments T follicular helper cell and antibody responses. Immunity 48, 584–598.e5 (2018).
Marino, E. et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552–562 (2017).
Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159–166 (2014).
Luu, M. et al. Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate. Sci. Rep. 8, 14430 (2018).
Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).
An, J. & Ha, E. M. Combination therapy of Lactobacillus plantarum supernatant and 5-fluouracil increases chemosensitivity in colorectal cancer cells. J. Microbiol. Biotechnol. 26, 1490–1503 (2016).
An, J. & Ha, E. M. Lactobacillus-derived metabolites enhance the antitumor activity of 5-FU and inhibit metastatic behavior in 5-FU-resistant colorectal cancer cells by regulating claudin-1 expression. J. Microbiol. 58, 967–977 (2020).
Encarnacao, J. C. et al. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J. Nutr. Biochem. 56, 183–192 (2018).
An, J., Seok, H. & Ha, E. M. GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABAB receptor signaling. J. Microbiol. 59, 202–216 (2021).
An, J. & Ha, E. M. Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells. J. Microbiol. 60, 735–745 (2022).
Dong, X. et al. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. Sci. Adv. 6, eaba1590 (2020).
Keefe, D. M. Intestinal mucositis: mechanisms and management. Curr. Opin. Oncol. 19, 323–327 (2007).
van Vliet, M. J., Harmsen, H. J., de Bont, E. S. & Tissing, W. J. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 6, e1000879 (2010).
Stein, A., Voigt, W. & Jordan, K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2, 51–63 (2010).
Haaz, M. C., Rivory, L., Jantet, S., Ratanasavanh, D. & Robert, J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol. Toxicol. 80, 91–96 (1997).
Yamamoto, M. et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol. Rep. 20, 727–730 (2008).
Cheng, K. W. et al. Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharmacol. Res. 139, 41–49 (2019).
Takasuna, K. et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 3752–3757 (1996).
Pedroso, S. et al. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 161, 1950–1960 (2015).
Brandi, G. et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin. Cancer Res. 12, 1299–1307 (2006).
Pollet, R. M. et al. An atlas of β-glucuronidases in the human intestinal microbiome. Structure 25, 967–977.e5 (2017).
Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).
Bhatt, A. P. et al. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy. Proc. Natl Acad. Sci. USA 117, 7374–7381 (2020).
Rousseau, B. et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N. Engl. J. Med. 384, 1168–1170 (2021).
Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).
Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).
Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
Xu, X. et al. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway. Front. Microbiol. 11, 814 (2020).
Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
Shaikh, F. Y. et al. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunol. Immunother. https://doi.org/10.1007/s00262-022-03169-6 (2022).
Si, W. et al. Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade. Gut 71, 521–533 (2022).
Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).
Li, Y. et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice. Nat. Commun. 10, 1492 (2019).
Griffin, M. E. et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373, 1040–1046 (2021).
Rizvi, Z. A. et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Sci. Adv. 7, eabg5016 (2021).
Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481–1489 (2020).
Wang, T. et al. Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. Nat. Metab. 2, 635–647 (2020).
Luu, M. et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).
Makino, S. et al. Enhanced natural killer cell activation by exopolysaccharides derived from yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. J. Dairy. Sci. 99, 915–923 (2016).
Bessell, C. A. et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight https://doi.org/10.1172/jci.insight.135597 (2020).
Fluckiger, A. et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936–942 (2020).
Gao, Y. et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal. Transduct. Target. Ther. 6, 398 (2021).
Goc, J. et al. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell 184, 5015–5030.e6 (2021).
Huang, J. et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front. Immunol. 13, 874922 (2022).
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
Zhang, S. L. et al. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes 14, 2046246 (2022).
Dizman, N. et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 28, 704–712 (2022).
Gao, G. et al. Adjunctive probiotic Lactobacillus rhamnosus Probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota. Front. Immunol. 12, 772532 (2021).
Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632–1640 (2021).
Zhuo, Q. et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci. Rep. 9, 20128 (2019).
Morishita, M. et al. Characterizing different probiotic-derived extracellular vesicles as a novel adjuvant for immunotherapy. Mol. Pharm. 18, 1080–1092 (2021).
Kawanabe-Matsuda, H. et al. Dietary lactobacillus-derived exopolysaccharide enhances immune-checkpoint blockade therapy. Cancer Discov. 12, 1336–1355 (2022).
Simpson, R. C. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med 28, 2344–2352 (2022).
Han, K. et al. Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat. Biomed. Eng. 5, 1377–1388 (2021).
Lam, K. C. et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 184, 5338–5356.e21 (2021).
Zhang, S. L. et al. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer. Theranostics 11, 4155–4170 (2021).
Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662–666 (2021).
Geiger, R. et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829–842.e13 (2016).
Gurbatri, C. R. et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aax0876 (2020).
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y. & Masia, R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am. J. Surg. Pathol. 41, 643–654 (2017).
Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804–1808 (2018).
Sun, S. et al. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc. Natl Acad. Sci. USA 117, 27509–27515 (2020).
Wang, T. et al. Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front. Immunol. 10, 1235 (2019).
Hundt, S., Haug, U. & Brenner, H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann. Intern. Med. 150, 162–169 (2009).
Imperiale, T. F. et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370, 1287–1297 (2014).
Guo, S. H. et al. A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin. Chem. 64, 1327–1337 (2018).
Liang, Q. Y. et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin. Cancer Res. 23, 2061–2070 (2017).
Wong, S. H. et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut 66, 1441–1448 (2017).
Xie, Y. H. et al. Fecal Clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. Ebiomedicine 25, 32–40 (2017).
Suehiro, Y. et al. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann. Clin. Biochem. 54, 86–91 (2017).
Liang, J. Q. et al. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. J. Gastroenterol. Hepatol. 36, 1035–1043 (2021).
Yang, J. et al. Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families. Gut Microbes 11, 918–929 (2020).
Lowenmark, T. et al. Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer. Sci. Rep. https://doi.org/10.1038/s41598-020-72132-1 (2020).
Gao, R. Y. et al. Gut microbiota dysbiosis signature is associated with the colorectal carcinogenesis sequence and improves the diagnosis of colorectal lesions. J. Gastroenterol. Hepatol. 35, 2109–2121 (2020).
Clos-Garcia, M. et al. Integrative analysis of fecal metagenomics and metabolomics in colorectal cancer. Cancers https://doi.org/10.3390/cancers12051142 (2020).
Shen, X. N. et al. Fecal enterotoxigenic Bacteroides fragilis–Peptostreptococcus stomatis–Parvimonas micra biomarker for noninvasive diagnosis and prognosis of colorectal laterally spreading tumor. Front. Oncol. https://doi.org/10.3389/fonc.2021.661048 (2021).
Yuan, B. A. et al. Fecal bacteria as non-invasive biomarkers for colorectal adenocarcinoma. Front. Oncol. https://doi.org/10.3389/fonc.2021.664321 (2021).
Liu, K. et al. The role of fecal Fusobacterium nucleatum and pks+ Escherichia coli as early diagnostic markers of colorectal cancer. Dis. Markers 2021, 1171239 (2021).
Yao, Y. Z. et al. A new biomarker of fecal bacteria for non-invasive diagnosis of colorectal cancer. Front. Cell. Infect. Microbiol. https://doi.org/10.3389/fcimb.2021.744049 (2021).
Osman, M. A. et al. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci. Rep. https://doi.org/10.1038/s41598-021-82465-0 (2021).
Wu, Y. et al. Identification of microbial markers across populations in early detection of colorectal cancer. Nat. Commun. 12, 3063 (2021).
Gao, R. Y. et al. Alterations of gut mycobiota profiles in adenoma and colorectal cancer. Front. Cell. Infect. Microbiol. https://doi.org/10.3389/fcimb.2022.839435 (2022).
Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).
Priya, S. et al. Identification of shared and disease-specific host gene–microbiome associations across human diseases using multi-omic integration. Nat. Microbiol. 7, 780–795 (2022).
Eklof, V. et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int. J. Cancer 141, 2528–2536 (2017).
Lee, J. K., Liles, E. G., Bent, S., Levin, T. R. & Corley, D. A. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann. Intern. Med. 160, 171 (2014).
Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1381–1390 (2014).
Sze, M. A., Baxter, N. T., Ruffin, M. T., Rogers, M. A. M. & Schloss, P. D. Normalization of the microbiota in patients after treatment for colonic lesions. Microbiome https://doi.org/10.1186/s40168-017-0366-3 (2017).
Yao, Q. L. et al. Potential of fecal microbiota for detection and postoperative surveillance of colorectal cancer. BMC Microbiol. https://doi.org/10.1186/s12866-021-02182-6 (2021).
Liang, J. Q. et al. Novel microbiome signatures for non-invasive diagnosis of adenoma recurrence after colonoscopic polypectomy. Aliment. Pharm. Ther. 55, 847–855 (2022).
Kwong, T. N. Y. et al. Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology 155, 383–390.e8 (2018).
Ma, C. et al. Establishing a novel colorectal cancer predictive model based on unique gut microbial single nucleotide variant markers. Gut Microbes 13, 1–6 (2021).
Bosch, S. et al. The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma. Gut Microbes 14, 2038863 (2022).
Du, X. H. et al. Alterations of the gut microbiome and fecal metabolome in colorectal cancer: implication of intestinal metabolism for tumorigenesis. Front. Physiol. https://doi.org/10.3389/fphys.2022.854545 (2022).
Bosch, S. et al. Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer. Gut Microbes 14, 2139979 (2022).
Mo, S. B. et al. Fecal multidimensional assay for non-invasive detection of colorectal cancer: fecal immunochemical test, stool DNA mutation, methylation, and intestinal bacteria analysis. Front. Oncol. https://doi.org/10.3389/fonc.2021.643136 (2021).
Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973–1980 (2016).
Li, X. & Saxena, D. The tumor mycobiome: a paradigm shift in cancer pathogenesis. Cell 185, 3648–3651 (2022).
Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315–324 (2022).
Lee, S. H. et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat. Microbiol. 6, 277–288 (2021).
Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).
Martini, G. et al. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. Int. J. Cancer 151, 473–480 (2022).
Pi, H., Huang, L., Liu, H., Liang, S. & Mei, J. Effects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer. Cancer Biomark. 28, 529–535 (2020).
Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022).
Gharaibeh, R. Z. & Jobin, C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut 68, 385–388 (2019).
Zhao, L. et al. Uncovering 1058 novel human enteric DNA viruses through deep long-read third-generation sequencing and their clinical impact. Gastroenterology 163, 699–711 (2022).
Li, Y. et al. Recovery of human gut microbiota genomes with third-generation sequencing. Cell Death Dis. 12, 569 (2021).
Kuchina, A. et al. Microbial single-cell RNA sequencing by split-pool barcoding. Science https://doi.org/10.1126/science.aba5257 (2021).
Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586–599 (2020).
Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532–537 (2019).
Ayukawa, S. et al. Epithelial cells remove precancerous cells by cell competition via MHC class I-LILRB3 interaction. Nat. Immunol. 22, 1391–1402 (2021).
Geyer, R. J., Tobet, R., Berlin, R. D. & Srivastava, P. K. Immune response to mutant neo-antigens: cancer’s lessons for aging. Oncoimmunology 2, e26382 (2013).
Dow, L. E. et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161, 1539–1552 (2015).
Federici, S. et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 185, 2879–2898.e24 (2022).
Acknowledgements
This project was supported by funds from Research Grants Council-General Research Fund (14101321; 24100520), RGC-Collaborative Research Fund (C4039-19G); Heath and Medical Research Fund (06170686; 08190706); and the Science and Technology Program Grant Shenzhen (JCYJ20170413161534162).
Author information
Authors and Affiliations
Contributions
C.C.W. researched data for this manuscript. Both authors discussed the content of the manuscript, and wrote, reviewed and/or edited the manuscript prior to submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Clinical Oncology thanks A. Chan who co-reviewed with C. Geraghty and W. Jia, who co-reviewed with H. Li and Y. Ni; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wong, C.C., Yu, J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol 20, 429–452 (2023). https://doi.org/10.1038/s41571-023-00766-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00766-x
This article is cited by
-
Mechanism of intestinal microbiota disturbance promoting the occurrence and development of esophageal squamous cell carcinoma——based on microbiomics and metabolomics
BMC Cancer (2024)
-
Cardiovascular disease and cancer: shared risk factors and mechanisms
Nature Reviews Cardiology (2024)
-
Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling
Cellular Oncology (2024)
-
Enterotoxigenic Bacteroides fragilis (ETBF) Enhances Colorectal Cancer Cell Proliferation and Metastasis Through HDAC3/miR-139-3p Pathway
Biochemical Genetics (2024)
-
Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence
Journal of Experimental & Clinical Cancer Research (2023)
